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Available online 14 May 2010Background: Depression is common in individuals with diabetes. The present study is the ﬁrst
randomized controlled trial to test the efﬁcacy of ω-3 ethyl-eicosapentaenoic acid (E-EPA) as
adjuvant to antidepressant medication in the treatment of depression in adults with diabetes
mellitus.
Methods: In the VU University Medical Center, we conducted a 12-week, placebo-controlled,
double-blind, parallel-group intervention study of E-EPA (1 g/day) versus placebo in 25 diabetes
patients meeting DSM-IV criteria for major depressive disorder, who were already using
antidepressant medication. The primary outcomewas severity of depressive symptoms, assessed
by theMontgomery Åsberg Depression Rating Scale (MADRS) at baseline and 12-week follow-up
at two-weekly intervals. Blood samples were collected at baseline and at 12-week follow-up to
determine EPA levels in erythrocyte membranes. Data were analyzed with ANOVA for repeated
measures.
Results: Thirteen participants were randomly assigned to E-EPA; 12 participants were given
placebo. At 12-week follow-up, erythrocyte membranes from patients receiving E-EPA contained
tripled levels of EPA, while no changes were noted in participants receiving placebo. In both
groups, depressive symptoms signiﬁcantly decreased over time (F=21.14, pb0.001), yet no
signiﬁcant differences were found between those treated with E-EPA versus placebo (F=1.63,
p=0.17).
Limitations: Although having sufﬁcient study power, this study had a relatively small sample size.
Small effects could not be detected, and dose-dependent effects could not be studied.
Conclusions:Noevidencewas found for the efﬁcacyof addingE-EPA to antidepressants in reducing
depressive symptoms in diabetic patients with co-morbid depression.
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Depression is a common co-morbid disorder in both type
1 and type 2 diabetes mellitus, and is associated with
impaired quality of life (Schram et al., 2009), poor glycemic
control (Lustman et al., 2000), increased health care costs
283M. Bot et al. / Journal of Affective Disorders 126 (2010) 282–286(Egede et al., 2002), and an increased all-cause mortality rate
(Egede et al., 2005). Cognitive behavioral therapy, tricyclic
antidepressants (TCAs), and selective serotonin reuptake
inhibitors (SSRIs) are effective treatments for major depres-
sion in diabetic patients (Lustman and Clouse, 2002).
However, a considerable percentage of diabetic subjects
receiving antidepressant drugs does not achieve full remis-
sion (TCAs: 43% and SSRIs: 52%) (Lustman and Clouse, 2002).
This ﬁnding highlights the need for further research on ways
how to improve treatment efﬁcacy in depressed patients with
diabetes. One candidate that could improve treatment success
may be longer chainω-3 polyunsaturated fatty acids (PUFAs)
from fatty ﬁsh, including eicosapentaenoic acid (EPA; C20:5
ω-3) and docosahexaenoic acid (DHA; C22:6 ω-3) (Pouwer
et al., 2005). Both depressed patients and diabetic patients are
known to have relatively low levels ofω-3 PUFAs (Decsi et al.,
2007; Sontrop and Campbell, 2006; Vessby, 2000). A recent
meta-analysis showed that ω-3 PUFAs were efﬁcacious as
antidepressant therapy (Appleton et al., 2010) , although
heterogeneity in study design was noted. However, a recent
study did not observe an effect of ω-3 PUFAs on mood in
depressed patients with a coronary heart disease (Carney
et al., 2009). Furthermore, there is some evidence that EPA
may be particularly effective as add-on treatment in patients
with major depression using antidepressant medication
(Pouwer et al., 2005; Sarris et al., 2009). The exact mechan-
isms of the relationship between depression and ω-3 PUFAs
remain to be elucidated, but could include increased
membrane ﬂuidity, altered cellular signaling processes,
altered neurotransmitter processing, and increased anti-
inﬂammatory activity (Parker et al., 2006; Pouwer et al.,
2005; Sarris et al., 2009).
The efﬁcacy of ω-3 PUFAs on depressive symptoms in
patients with diabetes mellitus is unknown. Therefore, we
conducted a double-blind, randomized, placebo-controlled
study to test the efﬁcacy of add-onω-3 ethyl-eicosapentaenoic
acid (E-EPA) on depressive symptoms in depressed diabetic
patients using antidepressant medication.2. Methods
2.1. Study design and participants
Participants were recruited from the VUMC diabetes
outpatient clinic and through advertisements on websites,
in newspapers, and patient magazines. Patients were eligible
if they were aged 18–75 years, diagnosed with diabetes (type
1 or type 2), and currently being on antidepressant
medication for at least twomonths. Furthermore, participants
had tomeet the criteria for currentMajor Depressive Disorder
(MDD), determined with the Composite International Diag-
nostic Interview (Andrews and Peters, 1998). Diabetes was
veriﬁed with the medical status when the patient attended
the VUMC. For those who were not patients of the VUMC,
persons who used insulin or oral hypoglycemic agents were
regarded as diabetes patients.
Exclusion criteria were: serious co-morbid disease, using
ﬁsh oil supplementation, consuming more than three
servings of ﬁsh per week, alcohol or drugs abuse, suicidal
ideation, and/or allergy to ﬁsh, ﬁsh products or rapeseed oil.Participants were recruited from April 2006 until May
2007 and the trial was performed between June 2006 and July
2007. The study protocol was approved by the ethical
committee of the VU University Medical Center (VUMC). All
participants gave informed consent.
2.2. Intervention
Patientswere randomly allocated to 1 g/day E-EPA or to an
equivalent dose of rapeseed oil+medium chain triglycerides
(placebo) for 12 weeks. This dosage and duration are in line
with other trials of ω-3 on depression (Appleton et al., 2010;
Peet and Horrobin, 2002). Both intervention and placebo
medicationwere provided in two soft gelatin capsules per day,
stabilized with mixed tocopherols, and were produced by
MinamiNutrition, Belgium. Patientswere advised not to chew
the capsules. Patients, research nurse and researchers were
blinded toward treatment allocation until completion of the
data collection.
2.3. Measurements
At baseline, demographic, anthropomorphic and health-
related characteristics were assessed at the VUMC. Severity of
depressive symptoms was assessed by the Dutch version of
the 10-item Montgomery Åsberg Depression Rating Scale
(MADRS) (Hartong and Goekoop, 1985), with a score range of
0–60. Higher scores reﬂect more severe depression.
The MADRS was administered at seven times during the
study by the research nurse. At baseline and in week 12, the
MADRS was administered in the VUMC. In week 1, 3, 5, 7, and
9 measurements of the MADRS were obtained per telephone.
A validation study showed that the MADRS can be reliably
administered by telephone instead of face-to-face (Hermens
et al., 2006).
Furthermore, in weeks 1, 3, 5, 7, 9, and 12 the research
nurse assessed whether the patient experienced one of the
following side effects: abdominal pain, belching, diarrhea, and
nausea. Other side effects were also noted. To study conceal-
ment, patients were asked whether they thought to be
allocated in the E-EPA group or the placebo group in week 12.
2.4. Blood samples
Blood was collected by venipuncture at baseline and in
week 12 and analyzed by the National Institute for Public
Health and the Environment. EPA levels in erythrocyte
phospholipids were measured with a gas chromatograph
(GC-3900, Varian Assoc., Palo Alto, USA). The EPA content was
expressed as percentage of the total fatty acids present in the
chromatogram. Hemoglobin A1c (HbA1c) is an indicator for
glycemic control (normal values: 4.3–6.1%) (Jeffcoate, 2004)
and was measured by a turbidimetric immuno inhibition
method using an auto analyzer (LX20-Pro, Beckman-Coulter,
Fullerton, USA).
2.5. Statistical analyses
Sample size was calculated with G*Power 3.0.10 for the
within–between interaction in Analysis of Variance (ANOVA).
Because we obtained seven repeated measures of depression
284 M. Bot et al. / Journal of Affective Disorders 126 (2010) 282–286symptom severity using the MADRS, 10 patients had to be
included in each treatment arm to detect an effect size of 0.25
(power=80%, two-sided α=0.05, correlation between re-
peatedmeasures=0.6 and non-sphericity correction ε=0.6).
Assuming a drop-out rate of 20%wehad to include a total of 25
patients.
Intention to treat analyses were conducted. Because
MANOVA for repeated measures has low power in small
samples (Stevens, 2002), the course of depression symptoms
was compared between both groups using ANOVA for
repeated measures by testing the signiﬁcance of the interac-
tion term treatment⁎ time, adjusted for the Greenhouse–
Geisser epsilon. Sensitivity analyses were performed by
excluding one person who discontinued E-EPA treatment
and two participants in the placebo arm who discontinued
using antidepressants during the study. The standardized
effect size was calculated by dividing the difference of change
in MADRS scores (from baseline to 12-week follow-up)
between the E-EPA and placebo group by their pooled
standard deviations. In all analyses, a 2-sided p value of
b0.05was used to determine statistical signiﬁcance. Statistical
analyseswere performedwith SPSS version 16.0 forWindows.
3. Results
3.1. Participant ﬂow
Fig. 1 presents the participant ﬂow during enrollment,
randomization and follow-up. Seventy-ﬁve patients wereFig. 1. Flow diagram of participawilling to participate in the study. Thirty-ﬁve patients declined
after they had received more detailed information about the
study. Furthermore, twelve patients were excluded because
they did not meet the inclusion criteria. The 25 eligible persons
for the trial were randomly assigned to either the E-EPA group
(N=13) and the placebo group (N=12). Onepatient receiving
E-EPA was lost to follow-up. From all other randomized
patients, all follow-up measurements were available. One
participant discontinued treatment during the trial due to an
allergic reaction to E-EPA (see below). Two participants (both
from the placebo group) ceased using antidepressants during
the trial. Table 1 provides the baseline characteristics of the
participants assigned to E-EPA and placebo.
3.2. EPA levels in erythrocyte membrane
From baseline to 12-week follow-up, the mean level of
EPA in the erythrocyte membrane tripled in the E-EPA group
(from 0.53% (±0.17) to (1.69%;±0.56)), whereas it
remained stable in the placebo group (from 0.66% (±0.20)
to (0.61%;±0.19)) supporting the integrity of the interven-
tion arms.
3.3. Course of depression symptom severity measured with the
MADRS
At baseline, the mean MADRS score was 26.3 (±8.2) in
the E-EPA group and 26.4 (±8.7) in the placebo group. At
12-week follow-up, the mean MADRS scores dropped tonts throughout the study.
Table 1








Mean SD Mean SD
Age (years) a 53.1 13.8 55.0 8.6 0.85
Body Mass Index (kg/m²) 29.3 5.1 29.8 4.8 0.80
Waist circumference (cm) a 99 15 100 14 0.98
N % N %
Women 8 62 5 42 0.32
Low educational level 3 23 5 42 0.41
Working full or part time 3 23 5 42 0.41
Living with a partner 7 54 9 75 0.41
Current smoker 0 0 3 25 0.10
Last month ﬁsh consumption ≥1
serving/week
3 23 4 33 0.67
Diabetes related N % N %
Type 1 diabetes 5 38 5 42 1.00
Type 2 diabetes 8 62 7 58 1.00
One or more diabetes
complications b
5 38 2 17 0.38
Treatment with diet 6 46 2 17 0.20
Treatment with oral blood glucose
lowering drugs
7 54 5 42 0.54
Mean SD Mean SD
Treatment with insulin 10 77 10 83 1.00
Duration of diabetes (years) 11.3 10.7 18.1 12.4 0.19
HbA1c (%) 6.9 1.1 6.9 1.1 0.91
Depression related
MADRS score 26.3 8.2 26.4 8.7 0.97
N % N %
Depression severity c
Mild 1 7.7 2 16.7 0.59
Moderate 11 84.6 7 58.3 0.20
Severe 1 7.7 3 25.0 0.32
Treatment d
Tricyclic antidepressant 2 17 0 0 0.48
Selective serotonin
reuptake inhibitor
9 75 10 91 0.64
Noradrenergic and speciﬁc
serotonergic antidepressant
1 8 1 9 1.00
a Mann–Whitney u test.
b Having nephropathy, retinopathy, diabetic foot, macrovascular compli-
cations, or neuropathy.
c Depression severity according to MADRS score: 9–17 mild depression,
18–34 moderate depression, and ≥35 severe depression (Muller et al.,
2000).
d At 12-week follow-up. Treatment was not speciﬁed for 1 person in the
E-EPA arm (loss to follow-up) and for 1 person in the placebo arm.
Fig. 2. Development of the MADRS score over time for the E-EPA (N=12)
and placebo group (N=12). Error bars indicate 95% conﬁdence interval. No
signiﬁcant treatment⁎ time interaction (F=1.63, df=3.98, p=0.17).
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placebo group (standardized effect size favoring placebo
d=0.29). Fig. 2 shows the development of the MADRS score
for the E-EPA group and the placebo group over time.
Repeated measures analysis revealed a statistically signiﬁ-
cant time effect: mean MADRS score decreased over time in
both groups (F=21.14, df=3.98, pb0.001). However, no
signiﬁcant effect of E-EPA treatment versus placebo over
time was found (treatment ⁎ time interaction ANOVA
F=1.63, df=3.98, p=0.17). Excluding one participant
who ceased using E-EPA during the study and two patients
who discontinued using antidepressantsmarginally changedthe results of the ANOVA (treatment⁎ time interaction
F=1.21, df=3.93, p=0.31). Furthermore, in the E-EPA
group, change in depression severity and change in E-EPA
level from baseline to 12-week follow-up were uncorrelated
(Pearson's r=0.016, p=0.96).
3.4. Side effects
Side effects were assessed at six occasions. Eight persons
never had a side effect. Prevalent side effects were stomach
ache (N=10), belching (N=7), nausea (N=6), and diarrhea
(N=5). Number and type of side effects did not differ
signiﬁcantly between the E-EPA and the placebo group. One
person assigned to the E-EPA group showed an allergic
reaction during the trial which consisted of rashes and
itching. No other serious side effects were reported.
3.5. Concealment
Concealment appeared to be successful. At 12-week
follow-up, only 4 of the 12 participants (33%) correctly
thought they received E-EPA, and 4 of the 12 (33%)
participants correctly thought they received the placebo.
4. Discussion
In the present randomized, double-blind placebo-controlled
study,we found no evidence of a therapeutic effect of 1 g/day
E-EPA as an add-on to antidepressant medication compared
to placebo in patients with diabetes and MDD during
12 weeks. This ﬁnding is not likely to be explained by a
lack of contrast between the two groups, as we observed
tripled levels of EPA in the erythrocyte membranes of
participants in the intervention group and no change in the
placebo group.
In a recent meta-analysis, Appleton et al. (2010) conclud-
ed that ω-3 PUFAs showed antidepressant efﬁcacy in non-
diabetic depressed patients, yet signiﬁcant heterogeneity in
study design was noted. Our results are in line with a recent
randomized controlled trial in coronary heart disease patients
with major depression that did not ﬁnd evidence that ω-3
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plus placebo for the treatment of depression (Carney et al.,
2009). However, there are clear differences between our
study and the other studies in sample characteristics
(diabetes patients vs. other patient groups) and the ω-3
PUFAs provided. Although EPA showed more promising
results on depression than DHA monotherapy (Pouwer
et al., 2005), it might be that a speciﬁc ratio of DHA and
EPA is more effective.
Strengths of our study included the small number of loss
to follow-up, the large number of follow-up measurements,
and its double-blind, placebo-controlled design. However, the
study is also subject to some limitations. Information about
ﬁsh consumption was only assessed at baseline. Yet, there
was no indication that the placebo group increased ﬁsh
consumption as the level of EPA did not increase. Also, we had
a heterogeneous sample of patients with respect to type of
diabetes and antidepressant use. In the case that E-EPAwould
be more effective in either type of diabetes or as add-on to a
speciﬁc type of antidepressant, our study sample was too
small to detect these effects. Furthermore, the dose of ﬁsh oil
in our study (1 g/day) and duration might not have been
adequate for patients with diabetes. Although we could not
ﬁnd studies about the effect of the placebo (rapeseed oil) on
mood, we cannot fully exclude the possibility that rapeseed
oil has some beneﬁcial effect on mood. Finally, although we
assessed the power of our study rigorously, we are aware that
our sample size is smaller than most other randomized
controlled trials. Therefore, the results may be more sensitive
for chance ﬂuctuations andwarrant future replication studies.
Clinical trials registration
ISRCTN Register. ISRCTN 30877831.
http://www.controlled-trials.com/ISRCTN30877831/
30877831
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